Accelerate to discover

Back to filter

Related topics

Cytek webinar : Improved flow cytometry assay resolution with autofluorescence extraction

Cytek Biosciences

Mar 30, 2021

The power of autofluorescence extraction in the detection of dim fluorescence on highly autofluorescent cells, and the...

Unleash Your Illumina Sequencer with TELL-Seq Linked Reads

Sage Science

Mar 24, 2021

Sage Science distributes universal sequencing technology´s TELL-Seq linked-read NGS library prep kits used with very...

Bruker webinar : High-resolution exploration of ESM-based vascularized tissue-flaps

Bruker Biospin

Mar 22, 2021

By employing a tissue engineering approach based on biological tissue constructs, Dr. Redenski has fabricated composite...

Apr 12, 2021

A real time-saver, accurate cell counting in 15 seconds with C100 counter

RWD

Mar 17, 2021

Cell counters are tools for counting live and/or dead cells in a culture. Any researcher who works in a cell culture...

Innovation never takes a break with IncuCyte

Sartorius

Mar 11, 2021

Analyze your cells for days, weeks or even months as they sit stationary in the stable environment of your tissue...

Imaging Flow Cytometry Luminex learning sessions

Luminex

Mar 5, 2021

Start the new year with new knowledge! Get the most from your Amnis instrument and IDEAS Software with training...

Apr 12, 2021

Preclinical lung imaging offers effective evaluation of drug candidates

Bruker Biospin

Mar 1, 2021

The incidence of respiratory disease is increasing throughout the world, and the demand for safe, effective drugs to...

Show all topics (10)

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Jun 1, 2018

The 10‐year survival rate of cancer patients has greatly increased over the last 20 years. However, the survival rate of patients with major malignant tumors, such as lung and pancreatic cancers, still shows negligible improvement.The conventional chemotherapeutic strategy for treating lung cancer remains unsatisfactory in this respect. Specifically, the 5‐year survival rates of both non‐small‐cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients exhibited merely 4–5% improvements in the past decade for cancer in stages I–III.2 The main difficulty in treating lung cancer is the lack of targeted chemotherapeutic agents specific to the lung tumor tissues and, thus, non‐specific targeting generally leads to unwanted side effects induced by excessive doses of chemotherapeutic agents.

Several strategies have been introduced to resolve the aforementioned issues, such as cancer antigen‐targeted monoclonal antibody (mAb) therapy,4 nanodrug delivery,5 and cell‐mediated therapy (i.e., T‐cell‐based therapy for NSCLC6). However, many clinical trials have shown that intravenously administered mAb, particularly epidermal growth factor receptor‐targeting mAbs, induced dermatological toxicities (e.g., acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, and hair/nail changes) in over 50% of patients after treatment.

Read more!

Scientific paper
Application

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Yokogawa

Yokogawa is a leading provider of confocal quantitative live cell imaging platforms. Combining superior technology with engineering services, project management, and maintenance, Yokogawa delivers field proven operational efficiency, safety, quality, and reliability. 

Related products

Confocal quantitative image cytometer CQ1 offers a new approach to image quantification

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey